Refractory Grade 1 Follicular Lymphoma

8 clinical trials · Condition

Record	Firm	Date
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT06859008)	City of Hope Medical Center	2025-08-25
Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (NCT06575686)	City of Hope Medical Center	2025-03-11
Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma (NCT06453044)	City of Hope Medical Center	2024-09-09
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma (NCT04635683)	Yazeed Sawalha	2022-09-30
CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL (NCT04995536)	City of Hope Medical Center	2021-07-27
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (NCT04659044)	Academic and Community Cancer Research United	2021-04-01
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma (NCT02568553)	National Cancer Institute (NCI)	2016-11-15
Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma (NCT02520791)	National Cancer Institute (NCI)	2016-09-13

Every clearance here is in the API, with alerts when new ones post.